I will draw three features from my member's bill around how the existing framework can be made better. Here are six proposals from the bill for how retail accessibility and affordability can be accelerated. The first is positioning of low-dose medicinal cannabis products on the over-the-counter framework. Secondly, provisional consenting from Medsafe. Thirdly, follow-up clinical trials—phase zero, phase one, and phase two only. Fourthly, controlled importing of approved quality, low-dose product. Five, GP prescribing without specialist co-signing. And six, pharmacy dispensing, as is done in the US. 